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ABSTRACT 
 
Background 
Standard treatment for osteosarcoma patients consists of a combination of cisplatin, 
adriamycin, and methotrexate before surgical resection of the primary tumour, followed by 
postoperative chemotherapy including vincristine and cyclophosphamide. Unfortunately, many 
patients still relapse or suffer adverse events. We examined whether common germline 
polymorphisms in chemotherapeutic transporter and metabolic pathway genes of the drugs used 
in standard osteosarcoma treatment may predict treatment response. 
 
Methodology/Principal Findings 
In this study we screened 102 osteosarcoma patients for 346 Single Nucleotide Polymorphisms 
(SNPs) and 2 Copy Number Variants (CNVs) in 24 genes involved in the metabolism or 
transport of cisplatin, adriamycin, methotrexate, vincristine, and cyclophosphamide. We 
studied the association of the genotypes with tumour response and overall survival. We found 
that four SNPs in two ATP-binding cassette genes were significantly associated with overall 
survival: rs4148416 in ABCC3 (per-allele HR = 8.14, 95%CI = 2.73-20.2, p-value = 5.1x10-5), 
and three SNPs in ABCB1, rs4148737 (per-allele HR = 3.66, 95%CI = 1.85–6.11, p-value = 
6.9x10-5), rs1128503 and rs10276036 (r2 = 1, per-allele 
HR = 0.24, 95%CI = 0.11–0.47 p-value = 7.9x10-5). Associations with these SNPs remained 
statistically significant after correction for multiple testing (all corrected p-values [permutation 
test] ≤0.03). 
 
Conclusions 
Our findings suggest that these polymorphisms may affect osteosarcoma treatment efficacy. If 
these associations are independently validated, these variants could be used as genetic 
predictors of clinical outcome in the treatment of osteosarcoma, helping in the design of 
individualized therapy. 
INTRODUCTION 
 
Osteosarcoma is the most frequent malignant bone tumour in children and adolescents. 
Standard treatment of osteosarcoma is based on a combination of different drugs: neoadjuvant 
therapy with methotrexate, cisplatin, and adriamycin followed by surgery and post-operative 
chemotherapy (methotrexate, cisplatin, adriamycin, cyclophosphamide, and vincristine). 
Despite this, approximately 30% of patients relapse or develop metastasis [1]. 
 
Clinical response to chemotherapeutics is a complex trait that is influenced by genetic and 
environmental factors. Anticancer therapies have a narrow therapeutic range so that a higher 
concentration in the patient’s body causes toxicity and a lower concentration reduces the 
efficacy of the drug. Interindividual differences in pharmacokinetics and pharmacodynamics 
determine the global response and toxicity profile of each drug. In this process, the genes 
involved are the ones that control drug absorption, distribution, metabolism, and excretion. The 
majority of metabolism reactions are catalyzed by the cytochrome P450 (CYP) enzymes [2]. 
Many chemotherapeutic agents are also metabolized by glutathione S-transferases (GSTs), 
phase II detoxification enzymes that catalyse the conjugation of glutathione (GSH) to a wide 
variety of xenobiotics [3]. Two types of transport superfamilies, ATPbinding cassette (ABC 
proteins) [4] efflux pumps and solute-linked carrier (SLC) influx proteins [5] are responsible 
for the majority of drug transport [6]. Most of the drug metabolizers and transporters contain 
many genetic polymorphisms, which might cause large interindividual variability in the plasma 
concentration of drugs. 
  
Pharmacogenetic studies have shown that germline polymorphisms in genes related to drug 
metabolism and transport can have a major effect on the pharmacokinetics and 
pharmacodynamics of these drugs [6]. We previously performed a study of the nucleotide 
excision DNA repair pathway in relation to response to cisplatin and observed an association 
between osteosarcoma outcome and a polymorphism in ERCC2 gene [7]. Nevertheless, a large 
portion of the interindividual variability in therapeutic response remains unexplained. 
 
Since mechanisms of transport and metabolism are shared between drugs, genetic variation 
could affect the bioavailability of more than one drug when they are used in combination, thus 
affecting the global response to treatment or causing adverse drug events. To address this, 
pharmacogenetic studies will need to focus on integration of multiple drug pathways to allow a 
more complete analysis of genetic factors influencing drug efficacy and toxicity. 
 
In the current study, we studied a comprehensive set of SNPs and CNVs that characterize the 
genetic variation of the multiple metabolic and transport pathways of drugs used in 
osteosarcoma treatment and their association with drug response. 
 
 
 
METHODS 
 
Patients, treatments, and clinical variables 
 
One hundred and two consecutive patients diagnosed with osteosarcoma at the University 
Clinic of Navarra, Pamplona, Spain, between 1986 and 2009 were enrolled in this study. All 
samples were obtained with written informed consent from patients, their parents, or both. 
Ethical approval of the study was granted by the Ethics Committee of the University Clinic. 
Patients were treated preoperatively with intravenous (i.v.) adriamycin (3 courses at 25–30 
mg/m2/day for 3 days), i.v. methotrexate (4 courses of up to 14 g/m2/day for 1 day) and intra-
arterial cisplatin (3 courses at 35 mg/m2/day for 3 days). After surgery, the adjuvant 
chemotherapy included methotrexate (10 g/m2/day for 1 day and folinic acid rescue) and 
alternate cycles of i.v. cisplatin/adriamycin or i.v. actinomycin D (0.45 mg/ m2/day for 3 days), 
cyclophosphamide (500 mg/m2/day for 3 days), and vincristine (1.5 mg/m2/day for 1 day) for 
up to 48 weeks of treatment. 
 
Response to treatment was determined histologically as the percentage of necrosis induced in 
the tumour after neoadjuvant chemotherapy. Patients with less than 90% necrosis were 
classified as poor responders and those with 90% necrosis or more, as good responders [8]. 
Overall survival was considered as the time from tumour diagnosis to death. Event-free-
survival (EFS) was considered as the time from tumour diagnosis to the first of disease 
recurrence, development of lung or bone metastases, and/or death. Patients who were alive at 
the last follow-up evaluation january, 2010) were censored at that time. Other clinical data 
including age, sex, tumour location, metastatic events (both at diagnosis and during follow-up) 
and relapses (disease recurrence in the same bone) were systematically recorded from the 
clinical records. Only conventional high-grade osteosarcomas were included, regardless of 
metastatic stage at diagnosis. 
 
 
DNA extraction and quantification 
 
Genomic DNA was extracted from peripheral blood lymphocytes using standard phenol-
chloroform extraction protocols. DNA was quantified using PicoGreen (Invitrogen Corp., 
Carlsbad, CA). 
 
  
Candidate genes and selection of polymorphisms 
 
A total of 24 candidate genes reported to be involved in the metabolism or influx/efflux of the 
five drugs (cisplatin, adriamycin, methotrexate, vincristine, and cyclophosphamide) were 
selected, based on the information available in the Pharmacogenomics Knowledge database 
PharmaGKB (www.pharmgkb.com). These genes encode the following proteins: 
 
Transporters: ABCA3, ABCB1, ABCC1, ABCC2, ABCC3, ABCC4, ABCG2, ABCC6, 
SLC31A1, SLCO6A1, SLC19A1; 
Phase I metabolism enzymes: MPO, SOD1, ALDH1A1, CYP3A4, 3A5, 2A6, 2B6, 2C8, 2C19, 
2C9; 
Phase II metabolism enzymes: GSTM1, GSTP1 and GSTT1. 
 
SNPs were selected across all these genes except for the GSTT1 gene. CNVs were studied in 
the GSTT1 and GSTM1 genes. 
 
TagSNPs for the selected genes were defined using Haploview software v.4.0 
(http://www.broad.mit.edu/mpg/haploview) with an r2 threshold of 0.8 and a minimum minor 
allele frequency of 0.05. All defined tagSNPs were selected for possible genotyping except 
those in the ABCC4 gene, for which an excessively elevated number of tagSNPs was defined 
and so a subset of 57 of these were selected. 
In addition, both SNPs with potentially functional effects (causing amino acid changes, 
potentially causing alternative splicing, in the promoter region, in putative transcription factor 
binding sites, or disrupting miRNAs and their targets) identified using the bioinformatics tool 
PupaSuite (http://bioinfo.cipf.es/ pupasuite/www/index.jsp), and other functional SNPs already 
described in the literature were selected. 
 
This preliminary list of SNPs was filtered using as criteria suitability for the Illumina 
genotyping platform (selecting only those with an assay score > 0.6, associated with a high 
success rate) and minor allele frequencies (MAFs) of at least 5%. 
 
A final number of 366 SNPs relevant to this study was included in an oligonucleotide pool 
assay for analysis using the Illumina Veracode technology (Illumina Inc., San Diego, CA). 
 
 
SNP Genotyping 
 
300 ng of DNA for each sample were genotyped using the GoldenGate Genotyping Assay with 
Veracode technology according to the published Illumina protocol. Data were analysed with 
GenomeStudio software for genotype clustering and calling. We excluded from further analysis 
SNPs with a call rate <0.95 and SNPs that deviated from Hardy-Weinberg equilibrium. 
 
Duplicate samples and CEPH trios (Coriell Cell Repository, Camden, NJ) were genotyped 
across the plates. SNPs showing Mendelian allele-transmission errors or showing discordant 
genotypes were excluded from the analysis. 
 
 
GSTM1 and GSTT1 copy number assays 
 
GSTT1 and GSTM1 copy number was calculated using Taqman Copy Number Assays 
(Hs00010004_cn probe for GSTT1 and Hs02575461_cn for GSTM1, Applied Biosystems, 
Foster City, CA) following the manufacturer’s protocol on an ABI PRISM 7900 Sequence 
Detection System (Applied Biosystems). RNAse P was used as the reference in TaqMan Copy 
Number Reference Assays. Data were analyzed using absolute quantification of resulting Ct 
values generated on the sequence detection system. Copy number was estimated using the 
CopyCaller 1.0 software (Applied Biosystems). Each sample was evaluated in triplicate. 
 
 
Statistical analysis 
 
Associations between tumour response and genotypes was assessed using logistic regression 
analysis [9], comparing genotype frequencies in poor responders versus good responders and 
estimating odds ratios (OR). Homozygotes for the most frequent allele were used as the 
reference group. SNPs were also assessed in relation to overall survival and event free survival 
(EFS) using Cox regression analysis [10]. Metastasis at diagnosis (no, yes) was included as 
covariate in multivariable logistic regression and Cox regression analyses. 
 
A permutation test was used to estimate p-values corrected for multiple testing. Each replicate 
consisted of randomly assigning the set of three variables, response to treatment, survival status 
and analysis time, across subjects and then carrying out the association analyses for each of the 
348 successfully genotyped variants and each of the two outcomes (response to treatment and 
survival). The minimum p-value of these 696 (= 348x2) tests was then recorded. Ten thousand 
such replicates were carried out and the corrected p-values were estimated as the proportion of 
replicate p-values less than the corresponding unadjusted p-value. Reported p-values are 
uncorrected for multiple testing, unless otherwise stated. Only SNP associations with corrected 
p-values <0.05 were considered statistically significant. 
 
Haplotypes containing rs1045642, rs2032582 and rs1128503 in ABCB1 were inferred by 
PHASE software, version 2.0. Association with overall survival was then assessed using Cox-
regression analysis. Kaplan-Meier curves were generated using SPSS (version 15.0, SPSS Inc., 
Chicago, IL, USA). All other analyses were carried out using PLINK or R (version 2.6.0.2). 
 
 
RESULTS  
 
Patients 
 
The main clinical data for the 102 osteosarcoma patients are presented in Table 1. The median 
age at diagnosis was 14 years (range 3 to 34 years). At the time of diagnosis, 21% of the 
patients already presented metastasis, while 22% developed metastasis during follow-up. The 
median follow-up time was 231 months (range 3–303). 
 
Response to treatment (necrosis) data were available for 91 patients and overall survival data 
were available for 101 patients. The percentage of good responders to therapy was 54 and the 
median overall survival was 219 months. 
 
Of the clinical variables analyzed, metastasis at diagnosis was found to be associated with 
increased risk of death (HR = 2.92, 95%CI = 1.35–6.28, p-value = 0.006). 
 
 
Association between polymorphisms and clinical data 
 
A total of 346 SNPs out of 366 and two CNVs were successfully analyzed. Eleven patients 
were removed for low genotyping call rate (<95%), so finally 91 patients were successfully 
analyzed. 
 
Results from the analysis of overall survival are presented in Table 1 and Figure 1. We 
identified four SNPs (two of them in complete linkage disequilibrium) in two genes that were 
associated with overall survival. The T allele of the synonymous SNP rs4148416 (G1013G) in 
the ABCC3 gene was associated with higher risk of death (per-allele HR = 8.14, 95%CI = 
2.73–20.2, p-value= 5.1x10-5, Figure 1A). In particular, the estimated five-year survival rate for 
patients carrying the CC genotype of rs4148416 was 78% compared to 20% for heterozygous 
patients. 
 
The G allele of s4148737, an intronic SNP located in the ABCB1 gene, was associated with 
poorer overall survival (per-allele HR=3.66, 95%CI=1.85–6.11, p-value=6.9x10-5,) Figure 1B). 
The estimated five-year survival rate for patients carrying the common AA genotype was 93% 
compared to 38% for patients homozygous for the G allele. The minor alleles of two other 
SNPs (rs1128503 and rs10276036) in this gene, in complete linkage disequilibrium (LD, r2 = 
1.0), and in partial LD with rs4148737 (r2 = 0.48), were also associated with better overall 
survival (per-allele HR = 0.24, 95%CI =0.11–0.47, p-value= 7.9x10-5, Figure 1C). For these 
two SNPs, the estimated five-year survival rate for common homozygotes was 49% compared 
to 100% for patients homozygous for the rare allele. These results did not change substantially 
after adjusting for metastasis at diagnosis (Table 2). All three associations remained statistically 
significant after correction for multiple testing (corrected p-value ≤ 0.030). 
 
We also studied these SNPs in relation to event-free survival (EFS) and highly consistent 
results were observed (Table 2). None of the SNPs analyzed were significantly associated with 
tumour response after correction for multiple testing. 
 
A combination of three SNPs located in ABCB1 (rs1045642 / rs2032582/ rs1128503) was 
previously described as putatively functional in several studies [4],[11],[12]. We explored 
whether there is a haplotype formed by these three SNPs that is more significantly associated 
with survival in these patients. We observed two frequent haplotypes, one formed by the 
combination of the three common alleles (CGC) with a frequency of 0.47 and the other 
comprising the three rare alleles (TTT) with a frequency of 0.39. Considering CGC as 
reference, the TTT haplotype was associated with better survival (HR = 0.31, 95%CI = 0.15–
0.62, p-value= 0.001). The other haplotypes observed had lower frequency and were not 
statistically significantly associated with survival. Nevertheless, the estimated HR for the two 
haplotypes containing the rare T allele in rs1128503 (CGT and CTT) were consistent with it 
having a protective effect (HR = 0.38 and 9.78x10-6, respectively) in contrast with the other two 
haplotypes containing the C wild-type allele (TGC and TTC; HR =1.26 and 1.95, respectively). 
These results suggested that the haplotypes were no more informative than the rs1128503 SNP 
alone. 
 
Regarding the CNVs analyzed, genotype data for GSTM1 and GSTT1 were available for 98 
and 99 patients, respectively. The frequency of the homozygous gene deletion was 52% (51 
patients) for GSTM1 and 19% (19 patients) for GSTT1. There was no evidence that either of 
these two polymorphisms were associated with any of the clinical outcomes considered. 
 
 
 
DISCUSSION 
 
This study assessed 346 SNPs and 2 CNVs in 24 key genes involved in platinum, adriamycin, 
methotrexate, vincristine, and cyclophosphamide pathways, and is the most comprehensive 
pharmacogenetic study in osteosarcoma patients to date. 
 
The use of large scale genotyping methods to screen multiple drug pathways has allowed us to 
identify four SNPs (two of them in total LD) that are highly associated with overall survival 
and that might be useful prognostic markers in these patients. 
 
To our knowledge, the majority of the pharmacogenetic studies are biased towards candidate 
polymorphisms in pharmacogenetic genes already described as functional in previously 
published data. However, given the complexity and the lack of understanding of both genetic 
variation effects and regulation of chemotherapy action, these polymorphisms explain only a 
portion of the observed phenotypic variability in the drug outcome. In our study, we have 
assessed all genes well-known to be involved in the metabolism and transport pathways of the 
drugs used in osteosarcoma treatment. In order to avoid any bias, we selected not only already 
described and potentially functional polymorphisms, but also tagSNPs, to obtain a more 
comprehensive view and to detect novel markers that could play a role in the interindividual 
differences observed of outcome risk in osteosarcoma patients. 
 
ABCC3 is a member of the multidrug resistance protein (MRP) family and is expressed in 
liver, gallbladder, kidney, and gut [13],[14]. Main substrates ofABCC3 are bile salts [15], but it 
also transports anticancer drugs, among which methotrexate [16], [17]. Vincristine, 
doxorubicin, and cisplatin have also been suggested to be ABCC3 substrates, but there are no 
clear results [17], [18]. The expression of ABCC3 mRNA has been related to drug resistance 
[16] but to date only limited studies have been published studying polymorphisms in ABCC3. 
Only promoter SNPs and non-synonymous SNPs have been investigated as potentially 
functional variants [19,20], but, to our knowledge, there are no studies showing association 
between these genetic ABCC3 variants and survival after treatment in cancer patients. In the 
present study we found that SNP rs4148416 in this gene was associated with an 8-fold risk of 
low survival and this is the first evidence of its clinical relevance. This SNP leads to a 
synonymous change (G1013G) at exon 22. The other SNPs we found associated with 
osteosarcoma survival are located in the ABCB1 gene. This gene is well-known and encodes a 
P-glycoprotein, an ATP-driven efflux pump, that is overexpressed in many tumours and confers 
multidrug resistance [21]. Of the drugs administered to these patients, both doxorubicin and 
vincristine are transported by this pump [22]. There are three variants in LD that have been 
studied in detail: 2677G>T/A (rs2032582), 3435C>T (rs1045642) and 1236C>T (rs1128503). 
The first is a non-synonymous change, while the other two are synonymous. These three SNPs 
have been studied both individually and as a haplotype, but the results have been inconsistent 
[4] [23] [11] [24]. The rare allele of rs1045642 has been reported to be associated with reduced 
P-glycoprotein activity, both alone and in combination with the rare alleles of rs2032582 and 
rs1128503 [23], [25]. These latter two variants have also been reported to have independent 
functional effects in different studies [12], [25], [26], [27]. However, it is still not clear which 
is/are the functional variant/s in this gene. 
 
In our study, of these three variants, only 1236T>C (rs1128503) was strongly associated with 
survival in our series of patients. This SNP leads to a synonymous change at residue 412 of the 
protein and is well-known but there is no clear consensus on its functional significance [28]. 
Some studies found increased response in the presence of the T allele [29], [30] while others 
found the opposite [31], or no genetic effect [32]. In our study, the T allele was associated with 
increased survival. To see if the association found was due to this single variant or to a 
combination of the three already described polymorphisms we also analyzed the effect of the 
haplotypes on overall survival. The results were consistent with a single main effect for 
rs1128503. Consistent results were reported by Balcerczak and colleagues in colorectal cancer 
patients [12]. 
 
We found another SNP, rs10276036, associated with survival that was in complete LD with the 
previous one. It is located in intron 9 and has been linked with reduced area under the curve 
(AUC) of SN-38, the active metabolite of CPT-11, [33]; however its functional significance is 
unknown. The effect observed could be explained by its correlation with rs1128503, rather than 
by rs10276036 itself. Apart from the already described SNPs, we found a polymorphism 
located in intron 17 (rs4148737) also strongly associated with survival. This SNP was in low 
LD with the other two SNPs. Further functional studies are needed to elucidate which is the 
causal variant in the ABCB1 gene. 
 
We hypothesize that the variants associated with overall survival could have an effect on the 
efflux of the drugs used in the treatment of osteosarcoma, thus impairing the response to the 
treatment and therefore the overall survival. Although we did not find a statistical association 
between these variants and tumour response, this could be explained by the fact that tumour 
response is evaluated after neoadjuvant therapy and at this point patients have been treated 
exclusively with methotrexate, cisplatin, and adriamycin. Therefore, the tumour necrosis data 
does not evaluate the effect of the vincristine and cyclophosphamide drugs used after surgery. 
Since ABCB1 is known to transport vincristine, ABCC3 could also be involved in this process 
[18,34], and the transport mechanisms for cyclophosphamide are still unknown, we postulate 
that genetic variation in these transporters could play a role in the effectiveness of the whole 
treatment and influence the overall survival. 
 
In conclusion, this study identified four significant SNPs in two drug transporter genes 
associated with overall survival in osteosarcoma patients. After validation in large and well-
defined sets of patients to confirm the associations, these variants could be useful as prognostic 
markers in these patients. 
 
Furthermore, the approach used in this study, integrating multiple drug pathways and studying 
an increased number of polymorphisms, may be extended to future pharmacogenetic studies to 
provide a wide scenario of genetic factors influencing drug efficacy and toxicity. The 
applicability of high-throughput gene chips that allow simultaneous analysis of multiple 
polymorphisms will facilitate research in this field. 
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Table 1. Clinical characteristics of 
osteosarcoma patients (N = 102). 
Patients 
 
N % 
Age at diagnosis   
Median 14.8  
Range 3–34  
Sex   
Female 45 44.1 
Male 57 55.9 
Location   
Femur 51 50.0 
Tibia 38 37.3 
Arm 7 6.9 
Central 6 5.9 
Response to treatment   
Good 52 57.1 
Poor 39 42.9 
Metastasis   
No 59 57.8 
At diagnosis 21 20.6 
At follow up 22 21.6 
Status   
Alive 72 71.3 
Dead 29 28.7 
Relapse   
No 85 83.3 
Yes 17 16.7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Genes and polymorphisms associated with overall survival (OS)                     
and event free survival (EFS). 
5-year OS HR* OS Adjusted**HR EFS HR 
(95%CI) (95%CI) (95%CI) SNP Genotype N survival    
rate P-value P-value P-value 
ABCC3       
rs4148416 CC 85 78%    
 CT 5 20%    
 per allele T   8.14 7.25 6.33 
    (2.73–20.2) (2.62–20.1) (1.79–12.7) 
    0.000051 0.00014 0.00028 
ABCBf       
rs4148737 AA 28 93%    
 AG 49 75%    
 GG 13 38%    
 per allele G   3.66 2.83 2.60 
    (1.85–6.11) (1.56–5.12) (1.24–3.22) 
    0.000069 0.00061 0.00051 
rs1128503 CC 26 49%    
 CT 50 82%    
 TT 14 100%    
 per allele T   0.24 0.27 0.42 
    (0.11–0.47) (0.13–0.54) (0.29–0.81) 
    0.000079 0.00023 0.0021 
rs10276036 TT 26 49%    
 TC 50 82%    
 CC 14 100%    
 per allele C   0.24 0.27 0.42 
    (0.11–0.47) (0.13–0.54) (0.29–0.81) 
    0.000079 0.00023 0.0021 
*HR: Hazard Ratio. 
**Analysis adjusted for metastasis at diagnosis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Kaplan-Meier survival curves for osteosarcoma patients according to genotype for 
(A) rs4148416 in ABCC3 (X2 = 21.4, p-value = 3.8x10-6); (B) rs4148737 in ABCB1 (X2 = 
18.4, p-value = 1.0x10-4); and (C) rs1128503 or rs10276036 in ABCB1 (X2 = 20.9, p-value = 
2.9x10-5).  
